tiziana-logo.png
Tiziana Life Sciences Announces Groundbreaking ALS Trial Grant Awarded by the ALS Association
November 19, 2024 07:00 ET | Tiziana Life Sciences Ltd.
NEW YORK, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
logo.png
Legendary Attorney Glenn Zeitz Launches Podcast: Philly Trial Lawyer Stories
October 24, 2024 10:00 ET | Glenn Zeitz
PHILADELPHIA, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Philly Trial Lawyer Stories, a new podcast from legendary attorney Glenn Zeitz, is set to launch on October 23rd offering listeners an exclusive,...
CytoMed logo.png
CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates
September 30, 2024 07:00 ET | CYTOMED THERAPEUTICS LIMITED
Conference call via Zoom is scheduled for October 8, 2024 at 9 a.m. ET (9 p.m. SGT) https://us06web.zoom.us/meeting/register/tZMrcOmppj0sGdA37lASywTyixRflo9w1TZT SINGAPORE, Sept. 30, 2024 (GLOBE...
Full Logo - OKYO .jpg
OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101
July 11, 2024 07:00 ET | OKYO Pharma LTD
Phase 2 randomized, placebo-controlled trial in neuropathic corneal pain (NCP) patients planned to begin in Q3, 2024OK-101 is believed to be the first IND clearance granted by FDA for a drug to begin...
Figure 1
OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease
July 10, 2024 07:00 ET | OKYO Pharma LTD
Encouraging 68% improvement in responder rate results from patients who achieved both the conjunctival staining “sign” and ocular pain “symptom” endpoints from the 240 patient Phase 2 Dry Eye Disease...
tiziana-logo.png
Tiziana Life Sciences Submits Grant Application to ALS Association to Fund Clinical Trial of Intranasal Foralumab
June 04, 2024 09:00 ET | Tiziana Life Sciences Ltd.
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
Trial Equity/Miller Tanner Partnership for Diversity
A Bold Step Forward: Trial Equity and Miller Tanner Associates Partner to Champion Diversity in Clinical Research
May 22, 2024 10:23 ET | Trial Equity
Trial Equity and Miller Tanner Associates are partnering to expand clinical trial participation to address the gap in diversity.
RAMM logo.jpg
RAMM Pharma Corp. Provides Update on Litigation
May 21, 2024 17:01 ET | RAMM Pharma Corp.
Not for Dissemination in the US or through US Newswire Services TORONTO, May 21, 2024 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM") (CSE:...
Y-Prime, LLC
YPrime Transforms Endocrinology and Autoimmune Trials through New Glucometer and eCOA Integrated Functionality
May 21, 2024 08:00 ET | Y-Prime, LLC
YPrime's new glucometer/eCOA functionality offers a patient-centric, intuitive, and connected experience to clinical trial participants.
July 30, 2021 - ROSEN LOGO.jpg
ALT INVESTOR NOTICE: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALT
May 09, 2024 14:52 ET | The Rosen Law Firm PA
NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of...